Anticoagulation therapy around catheter ablation for atrial fibrillation -Dabigatran vs. Warfarin-

Anticoagulation therapy around catheter ablation for atrial fibrillation -Dabigatran vs. Warfarin- - DAWN-AF Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006907

Enrollment

100

Registered

2011-12-19

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Dabigatran group 150 mg administered twice daily (2 capsules (75 mg), twice daily) The dosage should be reduced to 110 mg twice daily, as required. Warfarin group Administer once daily (adjust dosa

= 70 yrs, adjust dosage aiming at a PT-INR of 1.6 - 2.6. Blood samples should initially be collected once weekly until the INR stabilizes and then once monthly. However, many patients enrolled in this

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those patients who satisfy the following criteria will be eligible for entry to this study. 1. Patients in whom atrial fibrillation ablation is indicated A) Patients with Symptomatic AF B)Patients resistant to antiarrhythmic drug C) Left atrium diameter >= 55 mm D) No left atrial thrombus 2. Patients age 20-80 3. Patients must be able and willing to provide written informed

Exclusion criteria

Exclusion criteria: Patients who do not satisfy inclusion criteria

Design outcomes

Primary

Measure	Time frame
Total hospitalization period for the perioperative period of atrial fibrillation ablation	—

Countries

Japan

Contacts

Public ContactSeiji Takatsuki

Keio University School of Medicine Department of Cardiology

03-5843-6702

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026